ADAM17 and cancer: Since the expression of ADAM17 was found to correlate with tumor progression in breast cancer29, it was further hypothesized that ADAM17 produced by cancer cells might degrade IFN-γ in tumorigenic sites and thus attenuate IFN-γ-dependent cancer surveillance and anti-osteoclastogenic activity.